DS-7300a in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study intends to define the recommended Phase 2 dose of DS-7300a based on the efficacy,
safety, and pharmacokinetics (PK) results observed in participants with Pretreated
Extensive-stage Small Cell Lung Cancer (ES-SCLC) and to investigate DS7300a anti-tumor
activity in this population.